Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU5416 in Refractory/Relapsed Multiple Myeloma
NCT00006013Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Jun 2000
- Primary completion
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of semaxanib in multiple myeloma (MM), sponsored by Fox Chase Cancer Center. Started Jun 2000; status: completed.
02
Drugs
semaxanib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00006013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006013.